Sensorion SA (RFM.SG)

0,6620 +0,0040 (+0,61%) Ab 01:18PM CEST. Markt geöffnet.

Sensorion SA

375, rue du Professeur Joseph Blayac
Montpellier 34080
France
33 4 67 20 77 30
https://www.sensorion.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 57

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Nawal Ouzren	CEO & Director	N/A	N/A	1978
Mr. Bernd Schmidt	Chief Technical Officer	N/A	N/A	N/A
Dr. Geraldine Honnet M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Christine Le Bec	Head of CMC Gene Therapy	N/A	N/A	N/A
Ms. Stephanie Filipe	Head of the Project Management Office	N/A	N/A	N/A
Mr. Laurent Desire	Head of Preclinical Development	N/A	N/A	N/A
Rachel Cooper	Head of Audiology	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.

Corporate Governance

Sensorion SAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.